Patrick T. Bruck

机构：BioNTech (Germany) · ORCID：0000-0002-8278-3904

发表论文 90 篇 · 总被引 2133 次 · h-index 24

代表论文

Functional EPAS1 / HIF2A missense variant is associated with hematocrit in Andean highlanders (2024 · Science Advances · 被引 37)
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study (2024 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 被引 16)
1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition (2024 · 被引 9)
Abstract CT051: Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer (2024 · Cancer Research · 被引 8)
597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer (2023 · Regular and Young Investigator Award Abstracts · 被引 8)
1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50% (2023 · Annals of Oncology · 被引 4)